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Abstract 
Background: Septic coagulopathy represents a very dynamic disease entity, tilting from initial hypercoagulability 
towards a subsequent hypocoagulable disease state, entitled overt disseminated intravascular coagulation. Acute 
fibrinolysis shutdown has recently been described to be a crucial component of initial hypercoagulability in critically 
ill patients, although the underlying pathomechanisms, the specific temporal kinetics and its outcome relevance in 
patients with sepsis remain to be determined.
Methods: In total, 90 patients (30 with septic shock, 30 surgical controls and 30 healthy volunteers) were enrolled. 
Blood samples were collected at sepsis onset or prior and immediately after the surgical procedure as well as 3 h, 6 h, 
12 h, 24 h, 48 h and 7 d later, whereas blood samples from healthy volunteers were collected once. Besides viscoelas‑
tic and aggregometric point‑of‑care testing (POCT), enzyme‑linked immunosorbent and thrombin generation assays 
and liquid chromatography–mass spectrometry‑based measurements were performed.
Results: As assessed by viscoelastic POCT, fibrinolysis shutdown occurred early in sepsis. Significant increases in 
tissue plasminogen activator had no effect on thromboelastometrical lysis indices (LIs). Contrariwise, plasminogen 
activator inhibitor‑1 was already significantly increased at sepsis onset, which was paralleled by significantly increased 
LIs in patients suffering from septic shock in comparison with both control groups. This effect persisted throughout 
the 7‑day observation period and was most pronounced in severely ill as well as non‑surviving septic patients. Throm‑
boelastometrical LI, therefore, proved to be suitable for early diagnosis [e.g. LI 45 min: area under the curve (AUC) up 
to 0.933] as well as prognosis (e.g. LI 60 min: AUC up to 1.000) of septic shock.
Conclusions: Early inhibition of plasminogen activation leads to acute fibrinolysis shutdown with improved clot 
stability and is associated with increased morbidity and mortality in septic patients.
Trial registration This study was approved by the local ethics committee (Ethics Committee of the Medical Faculty of 
Heidelberg; Trial‑Code No. S247‑2014/German Clinical Trials Register (DRKS)‑ID: DRKS00008090; retrospectively regis‑
tered: 07.05.2015). All study patients or their legal representatives signed written informed consent.
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Background
Given the pathophysiological relationship between 
inflammation and coagulation, blood coagulation dis-
orders are very common in septic patients [1, 2]. How-
ever, septic coagulopathy represents a very dynamic 
disease entity, tilting from initial hypercoagulability 
towards a hypocoagulable disease state at later stages 
due to an excessive consumption of coagulation factors. 
Overt disseminated intravascular coagulation (overt 
DIC) represents the most serious form of hypoco-
agulable septic coagulopathy and is associated with an 
increased morbidity as well as mortality [3]. However, 
due to the lack of specific tests, most hypercoagulable 
blood coagulation disorders (which can be summa-
rized as non-overt DIC disease states) remain unidenti-
fied and the diagnosis of overt DIC is currently based 
on questionable scoring systems [such as the Interna-
tional Society on Thrombosis and Haemostasis (ISTH) 
score and the Japanese Association for Acute Medicine 
(JAAM) DIC score], which are both associated with 
relevant weaknesses. For example, the incidence of an 
overt DIC varies between 29 and 61% due to doubtful 
diagnosis criteria as well as differing calculation bases 
within the two scoring systems [4]. Accordingly, new 
approaches for a more sophisticated and stage-specific 
assessment of septic coagulopathy, comprising initial 
hypercoagulability as well as subsequent hypocoagu-
lable disease states, are absolutely warranted. From a 
pathophysiological point of view, septic coagulopathy is 
initially hallmarked by an excessive expression of tissue 
factor (TF), an inhibition of anticoagulant factors and 
a so-called fibrinolysis shutdown [3, 5]. Particularly, 
the phenomenon of fibrinolysis shutdown (as assessed 
by an increased thromboelastometrical LI) has already 
been identified as a crucial component of coagulopathy 
in critically ill patients, which was clearly associated 
with increased mortality for example in trauma patients 
[6]. However, detailed information about the underly-
ing pathomechanisms, the specific temporal kinetics 
and its outcome relevance in patients suffering from 
sepsis or septic shock is still lacking, so that additional 
well-designed clinical studies have to be demanded.
The aims of the presented study were therefore (1) to 
evaluate the pro- as well as anticoagulatory responses 
in septic coagulopathy and (2) to assess the detailed 
pathophysiology, kinetics and diagnostic and outcome 
relevance of fibrinolysis shutdown in patients suffer-
ing from sepsis by the use of modern viscoelastic and 
aggregometric point-of-care testing (POCT) devices as 
well as routine coagulation tests and elaborate labora-
tory methods.
Methods
Study participants, sample collection, DIC score and VTE 
prophylaxis
This prospective, observational, clinical study was 
approved by the local ethics committee (Ethics Com-
mittee of the Medical Faculty of Heidelberg; Trial-
Code No. S247-2014/German Clinical Trials Register 
(DRKS)-ID: DRKS00008090). All study patients or their 
legal representatives signed written informed consent. 
Between November 2014 and May 2016, 90 patients in 
three groups were enrolled in the study: (1) 30 patients 
with septic shock (according to the 2001 SCCM/ESICM/
ACCP/ATS/SIS International Sepsis Definitions Confer-
ence (Sepsis-2) [7]) following major abdominal surgery, 
(2) 30 patients undergoing major abdominal surgery 
with an uncomplicated course and (3) 30 age-matched 
healthy volunteers. The following criteria were defined 
as exclusion criteria: chronic inflammatory diseases, pri-
mary or acquired platelet dysfunctions, therapy with oral 
anticoagulants, pre-existing bleeding disorders, preg-
nancy or an age of younger than 18 years. Patients with 
septic shock were re-evaluated for survival at 30  days 
after enrolment in the study. The diagnosis of DIC was 
based on the validated score for overt DIC developed 
by the ISTH [8]. Relevant baseline data were collected 
at study inclusion in all study groups. In patients suf-
fering from septic shock, blood samples were collected 
at sepsis onset as well as 3  h, 6  h, 12  h, 24  h, 48  h and 
7  days afterwards. Blood samples from the surgical 
group were collected prior to surgery (pre), immediately 
after the surgical procedure (onset) and 3  h, 6  h, 12  h, 
24 h, 48 h and 7 days later. Viscoelastic  (ROTEM®) and 
aggregometric  (Multiplate®) POCT was performed at all 
timepoints, whereas clinical data, routine blood param-
eters and plasma samples for thrombin generation and 
enzyme-linked immunosorbent assays as well as liquid 
chromatography–mass spectrometry (LC–MS)-based 
measurements were only collected at pre (in surgical 
patients), onset (in patients with septic shock and surgi-
cal patients) and 24 h, 48 h and 7 d later. In the healthy 
control group, blood samples and clinical data were col-
lected only once. For prophylaxis of venous thrombo-
embolism (VTE), patients following major abdominal 
surgery received either intravenously (i.v.) administered 
low-dose (10.000  IU/day) unfractionated heparin (UFH) 
or subcutaneously (s.c.) administered low molecular 
weight heparin (LMWH; 40  mg enoxaparin/day) start-
ing from 6 h after the end of surgery. In patients suffer-
ing from septic shock, VTE prophylaxis was performed 
with i.v. low-dose (10.000 IU/day) UFH. None of the vol-
unteers in the control group received any anticoagulants.
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Viscoelastic POCT
Viscoelastic POCT in citrated whole blood was per-
formed with ROTEM  delta® (Tem International GmbH, 
Germany) restricted to ex-TEM® test, evaluating the 
extrinsic coagulation cascade. The following test param-
eters were recorded: (1) the clotting time (CT) repre-
sents the time needed from starting the test until the clot 
begins to rise. Depending on the test used, a prolonga-
tion of the CT may result from a consumption of coagu-
lation factors or the administration of anticoagulants. 
Contrariwise, shortening of CT represents an indicator 
for hypercoagulability. (2) The clot formation time (CFT) 
is described to be the time from CT (clot begins to rise) 
until a clot firmness of 20  mm has been reached. The 
CFT is mainly dependent on the platelet count as well 
as the fibrinogen level. A reduction in each factor is able 
to result in a prolongation of the CFT. (3) The lysis index 
(LI) is the percentage of the remaining clot firmness after 
45 min (LI 45) and 60 min (LI 60), indicating the amount 
of intrinsic fibrinolytic activity. All  ROTEM® measure-
ments were performed in duplicate.
Aggregometric POCT
Aggregometric POCT in hirudin-anticoagulated 
whole blood was performed on the multiple elec-
trode aggregometry (MEA) platelet function analyser 
 (Multiplate®; Roche Diagnostics GmbH, Germany). Test 
cells of this device incorporate a duplicate sensor for 
acceptance sampling. Platelets were stimulated in various 
ways: (1) via arachidonic acid (ASPI test; Roche Diagnos-
tics GmbH, Germany), (2) the ADP receptor (ADP test, 
Roche Diagnostics GmbH, Germany), (3) the thrombin 
receptor under the use of thrombin receptor-activating 
peptide-6 (TRAP test; Roche Diagnostics GmbH, Ger-
many) and (4) via the collagen receptor (COL test, Roche 
Diagnostics GmbH, Germany). Once initiated, platelet 
aggregation was allowed to run up to 6 min, and the area 
under the curve (AUC) was calculated.
ELISA measurements
Plasma levels of thrombin–antithrombin complex (TAT), 
plasminogen activator inhibitor 1 (PAI-1), free tissue 
plasminogen activator (tPA) and total tissue plasminogen 
activator (total tPA) were measured using enzyme-linked 
immunosorbent assay (ELISA) kits according to the man-
ufacturer’s instructions (Assaypro, St. Charles, USA). 
ELISA measurements were performed in duplicate.
TGA measurements
The thrombin generation assay (TGA; calibrated auto-
mated thrombogram; all reagents from Diagnostica 
Stago) was conducted with a validated method [9], in 
which thrombin generation was triggered in 80  µL of 
citrated platelet-poor plasma (PPP) by addition of a 
PPP reagent solution containing TF (final concentration 
5  µM) and phospholipids (final concentration 4  µM). 
After 5-min incubation time at 37  °C, 20 µL of the Flu-
Ca reagent was added. The activity of the thrombin gen-
erated resulted in conversion of a fluorogenic substrate. 
Fluorescence was measured continuously for 90 min with 
a MTP fluorometer (Diagnostica Stago), which relates 
the fluorescence to a thrombin calibrator. TGA parame-
ters (lag time, time to peak and peak height) were derived 
with Thrombinoscope software (Thrombinoscope, Maas-
tricht, The Netherlands).
LC–MS measurements
Extraction of 6-keto-prostaglandin F1α (PG F1α) and 
11-dehydro-thromboxane  B2 (11d-TX  B2) by liquid–liq-
uid extraction was performed as described previously 
[10]. The quantification via LC–MS/MS was performed 
with minor modifications [10]. Calibration range for each 
compound was as follows: PG F1α at 0.05, 0.1, 0.2, 0.4 
and 0.8 pmol for each calibrator per injection; 11d-TX  B2 
at 0.05, 0.1, 0.2, 0.4 and 0.8 pmol for each calibrator per 
injection.
For the detection of PG F1α and 11d-TX  B2, the param-
eters for electrospray ionization were set as follows: cap-
illary voltage—2.0 kV; desolvation temperature—300 °C; 
desolvation gas flow—850 L/h; source tempera-
ture—150  °C; cone gas flow—250 L/h; collision gas 
flow—0.15 mL/min; and nebulizer gas flow—5 bar. Cone 
and collision voltage was optimized for each compound 
separately: for PG F1α: retention time (Rt) 2.90 (min), 
mass transition (MRM) 369.1 > 163.2 (m/z), cone volt-
age (CV) 35 (V) and collision voltage (CE) 26 (V); and for 
11d-TX  B2: Rt 3.21 (min), MRM 367.1 > 305.3 (m/z), CV 
35 (V) and CE 15 (V).
Statistics and electronic database
Study data were entered into an electronic database 
 (Microsoft® Excel 2011, Microsoft Corporation, Red-
mond, USA) and evaluated using SPSS software (Statis-
tical Product and Services Solutions, version 24.0, SPSS 
Inc., Chicago, USA). Categorical data were summarized 
by means of absolute and relative frequencies. Quanti-
tative data were summarized using medians (with quar-
tiles). Wherever appropriate, data were visualized using 
line charts. The Kolmogorov–Smirnov test was applied 
to check for normal distribution. Due to non-normally 
distributed data, nonparametric methods for evalua-
tion were used (categorical data: Chi-square test/con-
tinuous data: Kruskal–Wallis test as a global testing 
procedure and Mann–Whitney test for pairwise com-
parisons as well as Friedman test and Wilcoxon test for 
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in-group comparisons). Furthermore, a receiver operating 
characteristic (ROC) analysis was performed with suitable 
parameters, in order to create cut-off values to determine 
the diagnostic or prognostic value of each parameter with 
regard to the diagnosis of sepsis and/or the estimation 
of outcome. A P value < 0.05 was considered statistically 
significant. Due to the explorative nature of the present 
investigation, no alpha adjustment was performed.
Results
Patient characteristics
All patients of the surgical control group underwent major 
abdominal surgery with an uncomplicated course. Patients 
in the septic group underwent major abdominal surgery 
as well, but suffered from septic shock due to a medical or 
surgical complication and were therefore hallmarked by a 
high disease severity at study inclusion as assessed by the 
APACHE II as well as SOFA scores. Relevant data of all 
study groups are presented in detail in Table 1.
Infection
Inflammatory and infection marker levels (such as leuco-
cyte count, C-reactive protein (CRP) and procalcitonin 
(PCT)) were shown to be increased in surgical and septic 
patients (Table 2). 
Increased intravascular formation of fibrin
The coagulation system was remarkably activated, in 
both the surgical and septic groups, whereas this effect 
was most pronounced in septic patients. Accordingly, 
patients with septic shock showed significantly increased 
levels of TAT complexes as well as D-dimers in com-
parison with patients of the surgical group throughout 
the whole observation period (Table 2). Moreover, anti-
coagulatory mechanisms, such as antithrombin (AT) III, 
protein S and protein C, were shown to be significantly 
impaired in the surgical as well as the septic groups in 
comparison with healthy volunteers, whereas this effect 
was again most pronounced in septic patients (Fig. 1a–c).
Decreased intravascular fibrin degradation
Plasma levels of total tPA and tPA were significantly 
increased in both the surgical and septic groups in 
comparison with healthy volunteers (Fig.  2a, b), which, 
however, did not result in a reduction in thromboelasto-
metrical LIs (LI 30 min, LI 45 min and LI 60 min) (Fig. 3a, 
b). On the contrary, plasma levels of PAI-1 were shown 
to be increased in both the surgical and septic groups in 
comparison with healthy controls (Fig.  2c), which was 
paralleled by a significant increase in viscoelastic LIs at 
45 min and 60 min. However, this effect was most pro-
nounced in patients with septic shock. Interestingly, LIs 
at 45 min and 60 min in surgical controls returned to the 
baseline level within 24 h, whereas fibrinolysis shutdown 
persisted throughout the whole observation period in 
patients with septic shock (Fig. 3a, b).
Consumption of coagulation factors
A consumption of procoagulant factors could be 
observed in patients suffering from septic shock, as indi-
cated by a decreased PT index and a prolonged activated 
partial thromboplastin time (aPTT) (Table  2). In line 
with that, CT values in ex-TEM® were significantly pro-
longed in the septic group up to 48 h after sepsis onset in 
comparison with the surgical group (Table 3). Moreover, 
thrombin generation as assessed by the lag time (Fig. 4a) 
and the time to peak (Fig. 4b) was significantly prolonged, 
and peak height (Fig. 4c) was significantly reduced in the 
septic group as compared to both control groups.
Impaired platelet function
Although the platelet count did not differ significantly 
between septic patients and surgical controls, platelet 
function was shown to be impaired in septic patients 
as assessed by aggregometric POCT (Table  3). As 
Table 1 Patients’ characteristics
Data are presented by median and interquartile range (Q1–Q3) or number and 
percentage
ASA status American Society of Anesthesiologists physical status classification 
system, SOFA score sepsis-related organ failure assessment  score, APACHE II score 
Acute Physiology and Chronic Health Evaluation II score
Healthy group
Age (years) 60 (56.3–65.0)
Gender (male) 20 (66.7%)
ASA status I; II; III; IV; V 3 (10.0%); 16 (53.3%); 11 (36.7%); 0; 0
Surgical group
Age (years) 60 (55.5‑73.5)
Gender (male) 21 (67.7%)
ASA status I; II; III; IV; V 2 (6.7%); 16 (53.3%); 12 (40.0%); 0; 0
Site of surgery (double naming feasible)
 Liver 8 (25.8%)
 Pancreas 14 (45.2%)
 Gastrointestinal 23 (74.2%)
Septic group
Age (years) 63.5 (53.8–73.0)
Gender (male) 23 (76.7%)
SOFA score (at Onset) 13.0 (12.0–14.5)
APACHE II (at Onset) 28.0 (25.3–32.8)
Primary site of infection/septic focus (double naming feasible)
 Surgical focus 28 (93.3%)
 Medical focus
  Pneumonia 5 (16.7%)
  Urinary tract infection 1 (3.3%)
Outcome
 Survivor 30 days 18 (60.0%)
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assessed by LC–MS measurements, PG F1α was sig-
nificantly increased in septic patients in comparison 
with both control groups throughout the whole obser-
vation period. In parallel, plasma levels of 11d-TX  B2 
were also increased in the septic group up to 48 h after 
sepsis onset, as compared to the surgical control group 
(Table 2).
Subgroup analyses
An overt DIC could be observed in 43.3% (n = 13) of 
the septic patients and 40.0% (n = 12) died within the 
30-day observation period. Patients with an overt DIC 
(n = 13) revealed a 23.8% decreased survival as com-
pared to non-overt DIC patients (n = 17). Moreover, 
overt DIC patients were hallmarked by a more pro-
nounced lysis shutdown as well as an accompanying 
consumption of coagulation factors in comparison with 
septic patients without DIC and healthy volunteers (e.g. 
at sepsis onset) (Additional file  1). Further subgroup 
analyses were performed with septic patients suffering 
from a high disease severity (SOFA score ≥ 18) as well 
as non-surviving septic patients (30-day mortality). It 
could be clearly demonstrated that fibrinolysis shut-
down was most pronounced in patients with a SOFA 
score ≥ 18 in comparison with those septic patients 
with a SOFA score < 18 (Fig.  5). The same holds true 
for non-surviving septic patients, in which fibrinolysis 
shutdown was significantly more pronounced in com-
parison with surviving septic patients (e.g. increased 
LI 60 min). As assessed by ROC analysis, the extent of 
fibrinolysis shutdown (e.g. LI 60 min) proved to be suit-
able for outcome estimation in patients suffering from 
septic shock (e.g. at onset: ROC area under the curve 
(AUC): 0.875 [95% CI 0.602–1.00]; at 3  h: ROC AUC: 
1.000 [95% CI 1.000–1.000]). Moreover, platelet func-
tion was also shown to be of prognostic value in sepsis, 
since COX-dependent (ASPI test and COL test), ADP-
dependent (ADP test) and TRAP-dependent (TRAP 
test) stimulation of platelets was significantly dimin-
ished in non-surviving septic patients in comparison 
with surviving septic patients at several timepoints 
throughout the whole observation period (Additional 
file 2).
Heparin effect
Since patients in the septic as well as surgical groups 
received either UFH (septic group) or enoxaparin (sur-
gical group) for VTE prophylaxis, specifically calibrated 
anti-Xa activities and thrombin time (TT), which is 
known to be more sensitive for UFH as compared to the 
aPTT, were measured in all groups in order to exclude 
relevant effects of both, UFH or enoxaparin, respec-
tively. However, anti-Xa activities and TT did not differ 
significantly between the three study groups, strength-
ening the hypothesis that neither the use of UFH, nor 
the administration of enoxaparin, had a relevant effect 
on patients’ coagulation status within the presented 
investigation (data not shown).
Fig. 1 Plasma levels of antithrombin (AT) III (a), protein S (b) and 
protein C (c) in healthy volunteers (n = 30; striped bars), surgical 
patients (n = 30; white bars) and patients with septic shock (n = 30; 
squared bars). Data of patients with septic shock and surgical patients 
are presented for the timepoints onset (sepsis onset or immediately 
after the surgical procedure) as well as 24 h, 48 h and 7 d later, 
whereas blood samples from healthy volunteers were collected 
only once. Data in box plots are given as median, 25th percentile, 
75th percentile with the 10th and 90th percentile at the end of the 
whiskers. A P value < 0.05 was considered statistically significant
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Discussion
An intensive crosstalk between the inflammation and 
coagulation systems is a well-known phenomenon, 
especially in critically ill patients [11–14]. In septic 
patients, pathogens trigger the release of a large vari-
ety of pathogen-associated molecular patterns [PAMPs; 
e.g. lipopolysaccharide (LPS)] [15], which are recog-
nized by so-called pattern recognition receptors (PRRs) 
on the cell surface of several immune cells (e.g. mono-
cytes). Subsequently, a variety of inflammatory media-
tors as well as large amounts of TF are released. The 
host response to a pathogen is invariably associated 
with coagulation activation, representing a prerequisite 
for sufficient pathogen clearance [11, 14, 16, 17] (graph-
ical summary—Fig. 6).
In line with this hypothesis, TF-mediated generation of 
thrombin as well as resulting fibrin formation was most 
pronounced in patients suffering from septic shock within 
the presented investigation. Accordingly, plasma levels 
of TAT and D-dimers were significantly increased in sep-
tic patients, indicating a compensatory need for ATIII-
associated inactivation of thrombin as well as an increased 
level of fibrin degradation resulting in significantly reduced 
plasma levels of ATIII in patients with septic shock in com-
parison with both control groups. In parallel, plasma levels 
of protein S and protein C were also shown to be signifi-
cantly reduced. The lack of these anticoagulatory mecha-
nisms represents a well-known phenomenon, especially 
in critically ill patients suffering from sepsis/septic shock 
[5], so that anticoagulant therapy was suspected to be of 
value in these patients [18, 19]. However, the efficacy of this 
strategy in sepsis remains a matter of dispute, since antico-
agulant therapy failed to show a clinical benefit in various 
clinical trials [20–23]. Of note, more differentiated analy-
ses [24–30] revealed a beneficial effect restricted to septic 
patients presenting with sepsis-induced DIC and/or suffer-
ing from a severe disease state. However, decision-making 
based on surrogates, such as the DIC or SOFA score, or the 
use of an unreflected time frame as the only decision crite-
rion may also result in incorrect or inadequate treatment. 
Although viscoelastic POCT was most frequently used for 
early detection of severe coagulation disorders in cases of 
severe or life-threatening bleeding events [31], POCT was 
also shown to be suitable for the detection of hypercoagu-
lability (e.g. due to hypofibrinolysis or accelerated throm-
bin formation in various disease states including sepsis) [5, 
32, 33]. Within this context, viscoelastic POCT may help 
Fig. 2 Total thrombin plasminogen activator (total tPA) (a), free 
thrombin plasminogen activator (tPA) (b) and plasminogen activator 
inhibitor‑1 (PAI‑1) plasma levels (c) of healthy volunteers (n = 30; 
striped bars), surgical patients (n = 30; white bars) and patients with 
septic shock (n = 30; squared bars). Data of patients with septic shock 
and surgical patients are presented for the timepoints onset (sepsis 
onset or immediately after the surgical procedure) as well as 24 h, 
48 h and 7 d later, whereas blood samples from healthy volunteers 
were collected only once. Data in box plots are given as median, 
25th percentile, 75th percentile with the 10th and 90th percentile at 
the end of the whiskers. A P value < 0.05 was considered statistically 
significant
Fig. 3 EXTEM lysis indices (LIs) at 45 min (a) and 60 min (b) in blood samples of healthy volunteers (n = 30; green dots), surgical patients (n = 30; 
blue dots) and patients with septic shock (n = 30; red dots). Data of patients with septic shock and surgical patients are presented for the timepoints 
onset (sepsis onset or immediately after the surgical procedure) as well as 3 h, 6 h, 12 h, 24 h, 48 h and 7 d later, whereas blood samples from 
healthy volunteers were collected only once. A P value < 0.05 was considered statistically significant
(See figure on next page.)
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to identify hypercoagulable patients likely to benefit from 
anticoagulant treatment.
Due to its pivotal role within the coagulation cascade, a 
more detailed analysis of thrombin homoeostasis in sep-
tic coagulopathy would be of great value [16]. Using an 
experimental pig model of LPS-induced sepsis, Schöchl 
et al. were able to show that endotoxaemia resulted in a 
significant acceleration of the non-activated TEM (na-
TEM®) CT very early after the end of LPS infusion (at 
2  h following LPS administration) [33, 34], which was 
not reflected by routine coagulation tests. However, one 
has to keep in mind that this effect might only be of tran-
sient nature and can completely turn into the opposite 
at later stages. As described by Schöchl et al., the initial 
decrease in CT in na-TEM® was followed by a significant 
increase in CT in na-TEM®, representing a sign for hypo-
coagulability at later stages. In line with these findings, 
CTs in both ex-TEM® and in-TEM® in patients of the 
septic group were shown to be significantly prolonged 
already at the clinical onset of sepsis, indicating a hypo-
coagulable disease state. In parallel, TGA measurements 
also revealed clear signs for a consumption of coagula-
tion factors in septic patients, as assessed by a prolonged 
lag time, a prolonged time to peak and a decreased peak 
height. Therefore, clot formation seems to be impaired at 
the timepoint of study inclusion, representing the clinical 
onset of sepsis.
Besides conversion of fibrinogen to fibrin, throm-
bin also closely interacts with the complement system, 
since it is able to cleave C3 to C3a and C3b and C5 to 
C5a and C5b, thus amplifying the activation of the com-
plement system. In addition to its well-established role in 
inflammation, C5a enhances blood thrombogenicity not 
only through the upregulation of TF (e.g. on endothe-
lial cells, neutrophils and monocytes) but also via PAI-1 
expression on various cell types (e.g. basophils and mast 
cells) [35]. TF expressed on various cells or released from 
injured cells initiates the physiologically most important 
TF (extrinsic) pathway, whereas PAI-1 is known to be a 
strong inhibitor of the fibrinolytic system. PAI-1-medi-
ated fibrinolysis shutdown has already been described 
in a pig model of endotoxin-induced DIC [33] as well 
as in human sepsis [36]. We were able to support these 
findings within the presented investigation. PAI-1 lev-
els were already increased significantly at sepsis onset, 
which was paralleled by significantly increased LIs in 
patients suffering from septic shock in comparison with 
both control groups. Therefore, thromboelastometrical 
LIs (e.g. LI 45 min) proved to be reliable biomarkers for 
early identification of patients suffering from sepsis or 
septic shock as already previously described [5, 37]. The 
observed fibrinolysis shutdown persisted throughout 
the 7-day observation period and was most pronounced 
in non-surviving septic patients as well as in those sep-
tic patients suffering from multiorgan failure, as assessed 
by high disease severity scores (SOFA). Accordingly, 
thromboelastometrical LIs (e.g. LI 60  min) were addi-
tionally shown to be reliable prognostic biomarkers for 
Fig. 4 Thrombin generation assay (TGA) lag time (a), time to peak 
(b) and  peak height (c) in healthy volunteers (n = 30; striped bars), 
surgical patients (n = 30; white bars) and patients with septic shock 
(n = 30; squared bars). Data of patients with septic shock and surgical 
patients are presented for the timepoints onset (sepsis onset or 
immediately after the surgical procedure) as well as 24 h, 48 h and 7 d 
later, whereas blood samples from healthy volunteers were collected 
only once. Data in box plots are given as median, 25th percentile, 
75th percentile with the 10th and 90th percentile at the end of the 
whiskers. A P value < 0.05 was considered statistically significant
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early identification of high-risk sepsis patients as already 
described by several other investigations [5, 38, 39]. The 
same holds true for trauma patients, in which fibrinolysis 
shutdown can be observed frequently and is also associ-
ated with a worse outcome [6]. Most interestingly and 
in line with results of Schöchl et  al. [33], the observed 
increases in PAI-1 were paralleled by significant increas-
ing plasma levels of total tPA and tPA in septic patients, 
which, however, had no effect on thromboelastometrical 
LIs (LI 30 min, LI 45 min and LI 60 min).
Platelets represent an essential element of primary 
haemostasis [40]. Besides, thrombocytopenia has been 
described to be a reliable predictor for the outcome of 
patients admitted to the intensive care unit (ICU) [41]. 
In line with the literature, septic patients within the pre-
sented investigation revealed significantly decreased 
platelet counts in comparison with healthy volunteers, 
whereas septic patients suffering from overt DIC revealed 
the lowest platelet counts [5, 42–45]. Besides decreased 
platelet counts, we were able to provide evidence for 
impaired platelet function in sepsis as compared to both 
control groups. Sepsis-associated changes in arachi-
donic acid metabolism might serve as an explanation for 
the observed impairments of platelet function in septic 
patients. Therefore, further examinations via an LC–MS-
based approach for the determination of 11d-TX  B2 (a 
stable and inactive metabolite of TXA2) and PG F1α (a 
stable and inactive metabolite of PGI2) were performed. 
TXA2 and PGI2 are supposed to be of importance in vas-
cular haemostasis as well as homoeostasis due to their 
opposing effects on vasoactivity and platelet aggregation 
[46–48]. On the one hand, PGI2 is known to be a potent 
inhibitor of platelet aggregation and acts as a vasodila-
tor. On the other, TXA2 induces platelet aggregation and 
acts as a potent vasoconstrictor. Since these two eicosa-
noids (both representing COX-dependent metabolites of 
arachidonic acid) are quite unstable, their inactive and 
stable hydrolysis products 11d-TX  B2 and PG F1α need 
to be determined as indirect surrogates for the TXA2 
and PGI2 loads in different inflammatory settings [47, 
49–51]. In summary, the present investigation revealed 
a strong upregulation of the anti-aggregatory PG F1α (as 
Fig. 5 EXTEM lysis index (LI) at 45 min in blood samples of healthy volunteers (n = 30; green dots), patients with septic shock and a sepsis‑related 
organ failure assessment (SOFA) score ≥ 18 (n = 5 at onset; blue dots) and patients with septic shock and a SOFA score < 18 (n = 25 at sepsis onset; 
red dots). Blood samples from healthy volunteers were collected once, whereas samples from patients with septic shock were collected at sepsis 
onset as well as 3 h, 6 h, 12 h, 24 h, 48 h and 7 d later. A P value < 0.05 was considered statistically significant
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a surrogate for PGI2), whereas the proaggregatory 11d-
TX  B2 (as a surrogate for TXA2) was shown to be down-
regulated at sepsis onset, resulting in strongly impaired 
haemostatic platelet function. Therefore, Yaguchi et  al. 
already hypothesized that sepsis seems to induce a redi-
rection of platelet function from haemostasis towards 
other non-haemostatic functions [45, 52].
Septic coagulopathy is a complex and dynamic dis-
ease entity, tilting from an initial hypercoagulopathy in 
non-overt DIC patients towards a hypocoagulable dis-
ease state in overt DIC patients, especially at later stages. 
However, the specific temporal kinetics of septic coagu-
lopathy is hallmarked by a high interindividual variabil-
ity and an assessment of initial hypercoagulability by the 
use of standard coagulation measurements is not feasible. 
What all this amounts to, is that up to now one cannot 
reliably predict the critical turning point from hyperco-
agulability to hypocoagulability in the individual patient 
in daily clinical routine. This problem might be solved 
by the use of modern viscoelastic POCT devices, since 
an initial hypercoagulability due to lysis shutdown, as 
indicated by an increased LI in viscoelastic POCT, in the 
presence of other viscoelastic signs for hypercoagulability 
(e.g. shortened CFT, etc.) might be used for the identifi-
cation of hypercoagulable septic patients likely to benefit 
from an anticoagulant treatment.
To the best of our knowledge, this is the first clinical 
study assessing detailed pathomechanisms, the specific 
temporal kinetics and the outcome relevance of septic 
coagulopathy at very early stages after sepsis onset by the 
use of a sophisticated coagulation monitoring (includ-
ing routine coagulation parameters, viscoelastic and 
aggregometric POCT, TGA, as well as an LC–MS- and 
ELISA-based evaluation of septic coagulopathy).
Limitations
The following limitations need to be addressed in con-
nection with the presented manuscript. The study was 
conducted in terms of a monocentric project, including 
only a limited number of patients. In the surgical con-
trol group, only patients undergoing major abdominal 
surgery were enrolled. Moreover, those patients most 
frequently suffered from a tumorous disease. This might 
have influenced the results, since tumour cells are able to 
activate blood coagulation through multiple mechanisms 
[53]. Accordingly, D-dimers were shown to be increased 
in surgical patients prior to the surgical procedure in 
comparison with healthy controls. The viscoelastic tests 
used within the presented investigation might have been 
not sensitive enough to identify minor changes within the 
fibrinolytic homoeostasis, so that a tPA-activated throm-
boelastometrical assay would have been of value for the 
Fig. 6 This graphical summary clarifies the most important findings of the presented investigation within the context of septic coagulopathy. 
PRR pattern recognition receptor, PAMP pathogen‑associated molecular pattern, AT III antithrombin III, TF tissue factor, TAT thrombin–antithrombin 
complex, tPA tissue plasminogen activator, PAI-1 plasminogen activator inhibitor 1, TGA thrombin generation assay, COX cyclooxygenase
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assessment of the magnitude of an ongoing fibrinoly-
sis shutdown. Besides, this decreased ability to detect 
minor changes is not only restricted to the evaluation of 
the fibrinolytic system, since the great amount of activa-
tor used in the different thromboelastometrical assays 
shifts the balance towards an over-activation in general. 
Furthermore, most patients in the septic group revealed 
an underlying abdominal focus, so that it has to be ques-
tioned critically whether these results can be transferred 
to septic patients with other foci without any limita-
tions. Moreover, it cannot be fully excluded that the low-
dose UFH treatment regime in septic as well as surgical 
patients might have had an influence on the presented 
test results, even though UFH and enoxaparin calibrated 
anti-Xa activity as well as thrombin time showed no sig-
nificant influence. Besides, since the study was designed 
for a maximal observation period of 30 days, conclusions 
regarding long-term outcome cannot be drawn.
Conclusions
Septic patients were shown to be hallmarked by an exces-
sive activation of the coagulation system, resulting in a 
consumption of pro- and anticoagulatory factors. An 
acute fibrinolysis shutdown occurred early after sep-
sis onset, as assessed by viscoelastic POCT, which was 
associated with an increased morbidity as well as mortal-
ity. Due to the consumption of coagulation factors and 
platelets, this initial hypercoagulability in non-overt DIC 
patients is tilting towards an overt DIC with a high risk 
of bleeding disorders at later stages. Our current findings 
clearly support the use of viscoelastic POCT in sepsis in 
order to stratify affected patients into hypo- and hyper-
coagulable, which might probably be used for the identi-
fication of hypercoagulable non-overt DIC patients likely 
to benefit from an anticoagulant treatment.
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